FDA Inspection 1165594 — University of Texas MD Anderson Cancer Center

University of Texas MD Anderson Cancer Center — FEI 3010547404

The FDA completed an inspection of University of Texas MD Anderson Cancer Center on March 24, 2022 in Houston, TX. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). 1 citation was issued during this inspection. Product area: Biologics.

Inspection Details

Classification
Voluntary Action Indicated (VAI) (VAI)
End Date
March 24, 2022
Fiscal Year
2022
Product Type
Biologics
Project Area
Human Cellular, Tissue, and Gene Therapies
Location
Houston, TX (United States)

Citations

IDCFRDescription
145421 CFR 211.115(a)Reprocessing procedures not written or followed